Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27

Benzinga · 2d ago
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $30 to $27.